Mutated Nucleotide Sequences of Batroxobin, Mutated Alpha Factor Secretion Signal Sequence and Processes for Preparing Batroxobin Using the Same
    1.
    发明申请
    Mutated Nucleotide Sequences of Batroxobin, Mutated Alpha Factor Secretion Signal Sequence and Processes for Preparing Batroxobin Using the Same 有权
    巴曲酶的突变核苷酸序列,突变的α因子分泌信号序列和使用其制备巴曲酶的过程

    公开(公告)号:US20110136207A1

    公开(公告)日:2011-06-09

    申请号:US12810902

    申请日:2008-12-23

    IPC分类号: C12N9/48 C07H21/04 C12N15/63

    CPC分类号: C12N9/6418 C07K2319/02

    摘要: The present invention relates to a batroxobin-encoding nucleotide sequence and/or a mutated α-factor secretion signal sequence, and a vector and a transformant using the same. The batroxobin-encoding nucleotide sequence of this invention exhibits an excellent expression efficiency in yeast, particular Pichia pastoris and the recombinant batroxobin is obtained at 4-13 fold higher yield than natural-occurring batroxobin-encoding sequences. The protein expression system which uses the batroxobin-encoding nucleotide sequence as well as mutated α-factor secretion signal peptide sequence of this invention obtains the recombinant batroxobin at about 20-fold higher yield than natural-occurring batroxobin-encoding sequences. In addition, the recombinant batroxobin prepared using the sequence of this invention has a significantly plausible activity and stability compared with natural-occurring batroxobin.

    摘要翻译: 本发明涉及一种编码巴曲酶的核苷酸序列和/或突变的α因子分泌信号序列,以及使用其的载体和转化体。 本发明的巴曲酶编码核苷酸序列在酵母,特别是巴斯德毕赤酵母中表现出优异的表达效率,并且以比天然存在的巴曲酶编码序列高出4-13倍的产量获得重组巴曲酶。 使用巴曲酶编码核苷酸序列以及本发明的突变型α因子分泌信号肽序列的蛋白质表达系统以比天然存在的巴曲酶编码序列高出约20倍的产量获得重组巴曲酶。 此外,使用本发明的序列制备的重组巴曲酶与天然存在的巴曲酶相比具有显着似乎合理的活性和稳定性。

    Mutated nucleotide sequences of batroxobin, mutated α factor secretion signal sequence and processes for preparing batroxobin using the same
    5.
    发明授权
    Mutated nucleotide sequences of batroxobin, mutated α factor secretion signal sequence and processes for preparing batroxobin using the same 有权
    巴曲酶的突变核苷酸序列,突变的α因子分泌信号序列和使用其制备巴曲酶的方法

    公开(公告)号:US08377676B2

    公开(公告)日:2013-02-19

    申请号:US12810902

    申请日:2008-12-23

    IPC分类号: C12N9/74 C12N15/57

    CPC分类号: C12N9/6418 C07K2319/02

    摘要: The present invention relates to a batroxobin-encoding nucleotide sequence and/or a mutated α-factor secretion signal sequence, and a vector and a transformant using the same. The batroxobin-encoding nucleotide sequence of this invention exhibits an excellent expression efficiency in yeast, particular Pichia pastoris and the recombinant batroxobin is obtained at 4-13 fold higher yield than natural-occurring batroxobin-encoding sequences. The protein expression system which uses the batroxobin-encoding nucleotide sequence as well as mutated α-factor secretion signal peptide sequence of this invention obtains the recombinant batroxobin at about 20-fold higher yield than natural-occurring batroxobin-encoding sequences. In addition, the recombinant batroxobin prepared using the sequence of this invention has a significantly plausible activity and stability compared with natural-occurring batroxobin.

    摘要翻译: 本发明涉及一种编码巴曲酶的核苷酸序列和/或突变的α因子分泌信号序列,以及使用其的载体和转化体。 本发明的巴曲酶编码核苷酸序列在酵母,特别是巴斯德毕赤酵母中表现出优异的表达效率,并且以比天然存在的巴曲酶编码序列高出4-13倍的产量获得重组巴曲酶。 使用巴曲酶编码核苷酸序列以及本发明的突变型α因子分泌信号肽序列的蛋白质表达系统以比天然存在的巴曲酶编码序列高出约20倍的产量获得重组巴曲酶。 此外,使用本发明的序列制备的重组巴曲酶与天然存在的巴曲酶相比具有显着似乎合理的活性和稳定性。

    Compositions for treating hyperproliferative vascular disorders and cancers
    6.
    发明授权
    Compositions for treating hyperproliferative vascular disorders and cancers 有权
    用于治疗过度增生性血管疾病和癌症的组合物

    公开(公告)号:US08106071B2

    公开(公告)日:2012-01-31

    申请号:US12528224

    申请日:2007-05-23

    IPC分类号: A01N43/42

    CPC分类号: A61K31/47

    摘要: The present invention relates to a method for treating or reducing the development of a hyperproliferative disorder, which comprises administering to a subject a composition, which comprises as an active ingredient the compound represented by the Formula 1: wherein R1, R2, R3, R4, R5, R6 and R7 independently represent hydrogen, halo, hydroxyl, cyano, amino, nitro, nitroso, carboxyl, C1-C12 alkyl, C2-C6 alkenyl, C3-C8 cycloalkyl, C5-C7 cycloalkenyl, C1-C6 alkylamino, C1-C6 alkoxy, aryl, heteroaryl, arylalkyl, arylalkenyl or alkylaryl; X and Y independently represent hydrogen, oxygen, or sulfur, bound to a carbon atom via a single or double bond; Z represents hydrogen, halo, hydroxyl, cyano, amino, nitro, nitroso, carboxyl, C1-C12 alkyl, C2-C6 alkenyl, C3-C8 cycloalkyl, C5-C7 cycloalkenyl, C1-C6 alkylamino, C1-C6 alkoxy, aryl, heteroaryl, arylalkyl, arylalkenyl, alkylaryl or —NH—R8; R8 represents hydrogen, halo, hydroxyl, cyano, amino, nitro, nitroso, carboxyl, C1-C12 alkyl, C2-C6 alkenyl, C3-C8 cycloalkyl, C5-C7 cycloalkenyl, C1-C6 alkylamino, C1-C6 alkoxy, aryl, heteroaryl, arylalkyl, arylalkenyl or alkylaryl; n is an integer of 0-3.

    摘要翻译: 本发明涉及一种治疗或减轻过度增殖性疾病发展的方法,其包括向受试者施用组合物,其包含作为活性成分的由式1表示的化合物:其中R1,R2,R3,R4, R5,R6和R7独立地表示氢,卤素,羟基,氰基,氨基,硝基,亚硝基,羧基,C1-C12烷基,C2-C6烯基,C3-C8环烷基,C5-C7环烯基,C1-C6烷基氨基,C1- C6烷氧基,芳基,杂芳基,芳基烷基,芳基烯基或烷基芳基; X和Y独立地表示通过单键或双键与碳原子结合的氢,氧或硫; Z代表氢,卤素,羟基,氰基,氨基,硝基,亚硝基,羧基,C1-C12烷基,C2-C6烯基,C3-C8环烷基,C5-C7环烯基,C1-C6烷基氨基,C1-C6烷氧基, 杂芳基,芳基烷基,芳基烯基,烷基芳基或-NH-R8; R8代表氢,卤素,羟基,氰基,氨基,硝基,亚硝基,羧基,C1-C12烷基,C2-C6烯基,C3-C8环烷基,C5-C7环烯基,C1-C6烷基氨基,C1-C6烷氧基, 杂芳基,芳基烷基,芳基烯基或烷基芳基; n为0-3的整数。